Expanding Global Access To Healthcare

This new five-year, $90 million investment in the Lilly Global Health Partnership will improve access to treatment for diabetes, cancer and tuberculosis and contribute to a company-wide effort to reach 30 million people annually by 2030 (known as the Lilly 30×30).

The Lilly Global Health Partnership researches new models of care, reports findings and advocates for the scale-up of the most effective solutions to help more people. Lilly will explore new approaches including drug discovery for diseases disproportionately affecting people in resource-limited settings; appropriate product delivery and packaging; alternative product pricing and patient financial assistance to improve access to care; strengthening health systems and local treatment capacity in communities with significant gaps in care; and new patient education programs.

for more information

Full IFPMA Partner Directory